What is one of the standard data elements that must be posted for applicable clinical trials according to the FDAAA?

The correct answer highlights the requirement for providing a brief summary of the study as one of the standard data elements that must be posted for applicable clinical trials under the FDA Amendments Act (FDAAA). This summary is essential because it provides a concise overview of the trial, including critical information such as the study's objectives, methodology, and outcomes. The inclusion of a summary not only helps to inform the scientific community and the public about the trial's intent but also promotes transparency and accountability in clinical research.

In contrast, while the locations of participating sites and the full results of studies may be relevant information, they are not specifically mandated under the standard data elements required by the FDAAA in the same way a study summary is. Furthermore, disclosing the names of every participant is not allowed due to confidentiality and privacy concerns. Therefore, the summary serves to balance the need for transparency with ethical considerations in participant privacy. This is why having a brief summary is a core requirement for reporting on clinical trials.